Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists

British Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 196-199

  Ohnishi, Ayako ^a   Ohtani, Hisakazu ^b   Sawada, Yasufumi ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Calcium antagonist; Determinant factor; Grapefruit juice; Interaction

Indexed keywords

AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; CALCIUM CHANNEL BLOCKERS; CITRUS PARADISI; DRUG INTERACTIONS; HUMANS;

EID: 33748269524     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02636.x     Document Type: Article

References (29)

1. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-53.
2. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998; 18: 251-72.
3. Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol 2000; 50: 455-63.
4. Watanabe A, Haruki S. ATELEC® Tab. In-house report. Tokyo: Ajinomoto Co., Inc 1999.
5. Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000; 67: 201-14.
6. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993; 36: 460-3.
7. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9.
8. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-42.
9. Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine-and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42: 313-7.
10. Hashimoto K, Shirafuji T, Sekino H, Matsuoka O, Sekino H, Onnagawa O, Okamoto T, Kudo S, Azuma J. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects. Eur J Clin Pharmacol 1998; 54: 753-60.
11. CONIEL® Tablets. In-house report. Tokyo: Kyowa Hakko Kogyo Co., Ltd 1995.
12. Sugawara K. Optimal use for drugs. Gekkan Yakuji (in Japanese). 1996; 38: 2591-6.
13. Yajima Y, Iijima H, Yokoyama R. Influence of grapefruit juice on the plasma concentration of efonidipine hydrochroride (Landel®). Jpn Pharmacol Ther (in Japanese). 2003; 31: 579-88.
14. Fuhr U, Maier-Bruggemann A, Blume H, Muck W, Unger S, Kuhlmann J, Huschka C, Zaigler M, Rietbrock S, Staib AH. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36: 126-32.
15. Sigusch H, Henschel L, Kraul H, Merkel U, Hoffmann A. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994; 49: 675-9.
16. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokin 1992; 22: 416-33.
17. Friedel HA, Sorkin EM. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988; 36: 682-731.
18. Package insert of ATELEC Tablets. Tokyo: Ajinomoto Co. Inc. 2003.
19. Interview Form (product information booklet) of CONIEL® Tablets. Tokyo: Kyowa Hakko Kogyo Co., Ltd 2004.
20. Yoshida K, Mitani M, Tsukamoto T, Naeshiro I, Shiraishi A, Yagi K, Kimura T, Shimomura H, Tanayama S. Disposition of manidipine hydrochloride [CV-4093 (2HCl) ], a new calcium antagonist, in rats and dogs. Jpn Pharmacol Ther (in Jap) 1989; 17: 2083-117.
21. Interview Form (product information booklet) of Landel®. Osaka: Shionogi Ltd 2003.
22. Interview Form (product information booklet) of Amlodin®. Osaka: Sumitomo Pharmaceuticals 2003.
23. Interview Form (product information booklet) of Herbesser®. Osaka: Tanabe Seiyaku Co. Ltd 2003.
24. Interview Form (product information booklet) of Baymycard®. Osaka: Bayer Yakuhin Ltd 2003.
25. Diez I, Colom H, Moreno J, Obach R, Peraire C, Domenech J. A comparative in vitro study of transdermal absorption of a series of calcium channel antagonists. J Pharmaceut Sci 1991; 80: 931-4.
26. Miyakoda G, Nakayama N, Matsui K, Yabuuchi Y. Mechanisms of the potent and long-lasting antihypertensive action of the new calcium channel blocker pranidipine. Drug Res 1995; 45: 471-5.
27. Masumoto K, Takeyasu A, Oizumi K, Kobayashi T. Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (logP) by high performance liquid chromatography (HPLC). Yakugaku Zasshi (in Japanese) 1995; 115: 213-20.
28. Pang DC, Sperelakis N. Uptake of calcium antagonistic drugs into muscles as related to their lipid solubilities. Biochem Pharmacol 1984; 33: 821-6.
29. Yamada Y, Ito K, Nakamura K, Sawada Y, Iga T. Prediction of therapeutic doses of beta-adrenergic receptor blocking agents based on quantitative structure-pharmacokinetic/pharmacodynamic relationship. Biol Pharm Bull 1993; 16: 1251-9.